Drugs / GBS III-TT
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00128219 | Jul 2003 → Dec 2008 | group B streptococcal infection | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | Met primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GBS III-TT | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00128219 ↗ |
| Modality | Vaccine | “A GBS type III capsular polysaccharide (CPS)-tetanus toxoid conjugate (III-TT) vaccine was evaluated for safety and efficacy in preventing acquisition of GBS colonization.” PMID 30281066 ↗ May 2019 |
| Route | Intramuscular | “A single dose of GBS III-TT vaccine administered intramuscularly (IM)” NCT00128219 ↗ |